• Avadel Pharmaceuticals plc (NASDAQ: AVDL) announced that the United States District Court for the District of Delaware ordered Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) to delist U.S. Patent No. 8731963 (the REMS Patent) from the FDA Orange Book. 
• With this decision, Avadel seeks to accelerate the FDA's final approval for Lumryz, a once-at-bedtime formulation of sodium oxybate for cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
• In July, Lumryz received tentative approval from the FDA, with potential final approval pending the disposition of the REMS Patent. 
• Price Action: Avadel Cuts Workforce, Optimizes Cost Structure.
• In October, a Markman hearing was held in which Avadel renewed its request for expedited consideration of its pending motion to have the REMS Patent delisted from the FDA's Orange Book. 
• The Delaware Court granted that request and held a hearing on that motion. 
• Avadel is currently evaluating the long-term safety and tolerability of Lumryz in the open-label RESTORE clinical study. 
• Price Action: AVDL shares are 0.12% lower at $8.01 during premarket trading on Monday.

See more from Benzinga

• Warren Buffett's Berkshire Boosts Stake In Five Japanese Trading Houses
• Carvana Faces Heat Of Slowing Demand, Higher Interest Rates

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.